Topic - Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees. The company's name and logo refer to the Balm of Gilead. Gilead (a place mentioned in the Bible) was famed for its small trees that produced a resin used in medicine. - Source: Wikipedia

Related Stories

FILE - A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, July 23, 2024. (AP Photo/Nardus Engelbrecht, File)

Eswatini is the first African country to get twice-yearly HIV prevention shot

By FARAI MUTSAKA - Associated Press

A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead's lenacapavir drug trial. (AP Photo/Nardus Engelbrecht) **FILE**

FDA approves the world’s only twice-a-year shot to prevent HIV

By Lauran Neergaard - Associated Press

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

Abusing Bayh-Dole Act for remdesivir would further jeopardize COVID-19 research

By David Winwood

Scientific Games; Nvidia rise; Marathon Oil, Hologic fall

Associated Press

FILE - This April 30, 2020, file photo shows Gilead Sciences headquarters in Foster City, Calif. Shares of Immunomedics more than doubled before the market open on Monday, Sept. 14 after Gilead Sciences said it'll buy the biotechnology company for $21 billion. (AP Photo/Ben Margot, File)

Gilead Sciences buying Immunomedics in $21 billion deal

Associated Press

A man walks in the rain past an electronic stock board showing Japan's Nikkei 225 index at a securities firm in Tokyo Friday, July 10, 2020. Asian stock markets followed Wall Street lower Friday on worries economic improvements might fade as coronavirus cases increase in the United States and some other countries. (AP Photo/Eugene Hoshiko)

Wall Street rallies as optimism returns to cap erratic week

By STAN CHOE and DAMIAN J. TROISE and ALEX VEIGA - Associated Press

President Donald Trump signs his name on a piece of paper during a roundtable with governors on the reopening of America's small businesses, in the State Dining Room of the White House, Thursday, June 18, 2020, in Washington. (AP Photo/Alex Brandon)

Health experts slam US deal for large supply of virus drug

By MARIA CHENG - Associated Press

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. Gilead Sciences announced the price Monday, June 29 for remdesivir, and said the price would be $3,120 for patients with private insurance. It will sell for far less in poorer countries where generic drugmakers are being allowed to make it. (AP Photo/Ben Margot, File)

Gilead’s $2,340 price for coronavirus drug draws criticism

By MARILYNN MARCHIONE - Associated Press

New Jersey Gov. Phil Murphy wears a mask during his daily coronavirus news conference at the War Memorial, Tuesday, May 19, 2020, in Trenton, N.J. (Chris Pedota/The Record via AP, Pool)

Governors roll back reopenings as coronavirus cases explode

By Tom Howell Jr. and Shen Wu Tan - The Washington Times

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) ** FILE **

HHS: U.S. has secured 500K courses of remdesivir, a COVID-19 treatment

By Tom Howell Jr. - The Washington Times

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. (Gilead Sciences via AP) ** FILE **

Gilead to start trials of inhaled remdesivir for COVID-19 in August

By Shen Wu Tan - The Washington Times

In this March 2020 file photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP) ** FILE **

U.S. government anticipated to run out of remdesivir by end of June

By Shen Wu Tan - The Washington Times

FILE - This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif. A California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19. Gilead Sciences gave few details on Monday, June 1, 2020, but said full results would soon be published in a medical journal. (AP Photo/Ben Margot, File)

Gilead says drug helped moderately ill coronavirus patients

By MARILYNN MARCHIONE - Associated Press

President Donald Trump speaks during a meeting with restaurant industry executives about the coronavirus response, in the State Dining Room of the White House, Monday, May 18, 2020, in Washington. (AP Photo/Evan Vucci)

Donald Trump taking hydroxychloroquine to stave off coronavirus

By Tom Howell Jr. - The Washington Times

In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. On Wednesday, the company says its experimental antiviral drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. (Gilead Sciences via AP) ** FILE **

FDA authorizes emergency use of remdesivir for COVID-19 patients, Trump says

By Tom Howell Jr. - The Washington Times